Moderna (MRNA) shares have risen more than 650% this year on enthusiasm for its cancer vaccine intismeran, which is not yet approved. Clinical trial results combining intismeran with Merck's Keytruda have been highly effective in reducing the risk of death or recurrence in melanoma patients, and Merck and Moderna are evaluating it for other cancers, including non-small cell lung cancer. Still, as of the end of last week the stock was down around 36% over five years. The article says the stock would need a valuation of around $180 billion to double, and that it may not be appropriate for investors with a low risk tolerance.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Modernapharmaceuticalshealthcarecancer vaccine
Open a keyword to see other news on the same topic.
Related news
- Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
Moderna shares fell 7% to $185.74 in morning trading after its personalized melanoma vaccine, intismeran autogene, given with Keytruda, met its primary goal of reducing the risk of recurrence or death, but its effect on distant metastasis was far smaller than an earlier mid-stage study suggested. Detailed late-stage results were released on October 22 ahead of a conference in Madrid. BioNTech fell 3% to $85.65, Merck fell 0.2% to $145.61 and Pfizer fell 0.2% to $29.96, while the iShares Biotechnology ETF rose 0.2% to $208.21. The article notes Moderna's business relies entirely on mRNA medicines, so the vaccine carries a large share of its pipeline value, and says the next step is whether the full dataset supports a regulatory filing.
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
Moderna is among the year's hottest stocks due to its personalized cancer treatment. Full Phase 3 data are scheduled to be released this weekend.
- Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
Moderna shares fell 4% to $193.62 in morning trading, extending an 18% plunge from the prior session, even though full late-stage data for its personalized melanoma vaccine, given with Merck's Keytruda, came back positive. Compared with Keytruda alone, the combination cut the risk of melanoma recurrence or death, a result near analyst expectations but short of the highest hopes built during a rally that began in August. The vaccine carries far more weight for Moderna, whose approved products are all respiratory vaccines, while for Merck it is an add-on to Keytruda; Merck fell 0.8% to $146 and Pfizer 0.7% to $30.22. The iShares Biotechnology ETF was unchanged at $209.54, suggesting the slide is company-specific. The full data will be presented at a medical conference this weekend.
- If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting Started
Moderna (MRNA) is the best-performing stock in the S&P 500 this year, up around 650%, ahead of Sandisk at about 380%. The shares had struggled after sales fell sharply as demand for its COVID vaccine and pill dwindled. Attention now centers on intismeran, a cancer vaccine developed with Merck, which in a late-stage trial reduced the risk of death or recurrence in melanoma patients by 42% when paired with Keytruda. CEO Stéphane Bancel believes it will work everywhere Keytruda works, a drug that brought Merck $32 billion in revenue last year. The article cautions that intismeran is not yet approved, Moderna's revenue totaled just $1.9 billion in 2025, and its market value is under $90 billion versus Merck's around $370 billion, so investors should tread carefully.
- Stock Split Watch: Is Moderna Next?
Moderna's stock has soared 650% this year after a few years of weakness, driven by earnings improvements and a focus on oncology and rare disease candidates, though it remains far below its pandemic-era record and trades 60% above analysts' estimates. The article explains that a stock split mechanically lowers the share price in proportion to the ratio without changing a company's valuation, and companies often split after strong gains push prices to high levels. Moderna has not yet done a stock split. The author notes that positive phase 3 results for its personalized cancer vaccine in melanoma, a possible regulatory submission, and about nine additional trials are potential catalysts, so Moderna may not split just yet.
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
Investors had 'incredibly high' expectations for Phase 3 data on the drugmaker's experimental cancer treatment.
Related markets
Latest news
- SLV Crashes To Near 52-Week Lows, GLD Falls Pre-Market – World Gold Council Cuts 2026 Gold Investment Forecast By Half
Gold and silver fell sharply as investors weighed the U.S. midterm elections, Middle East tensions and a rebound in oil prices; SLV dropped 3.2% to its lowest in nearly 52 weeks, while GLD slipped over 1.1% in pre-market trading. January 2027 gold futures fell 1.4% to $3,929.80 per ounce, and silver contracts due in January 2027 dropped 3.8% to $49.20 per ounce. Saxo Bank's Ole Hansen said gold was sold again near $3,970 an ounce, a former support level that has become resistance, pointing to fragile sentiment. KCM Trade's Tim Waterer said a convincing move above $4,000 an ounce would signal improving momentum, and warned that a tech selloff driven by regulatory pressure could spill over into gold as positions are cut to cover losses. The World Gold Council cut its 2026 full-year gold investment demand forecast to 200 metric tons from 400 MT, as demand for bars and coins fell 19% in the third quarter.
- Midterm elections could jolt stocks if Democrats sweep Congress
The stock market is not yet pricing in a Democratic sweep of Congress, though polls and most prediction markets point that way, investors and analysts said. JPMorgan sees a blue wave knocking the S&P 500 down about half a percent on Wednesday, while a Republican hold could spur a short-term rally. A Democratic win, especially in the Texas governor race, could add pressure to AI stocks over possible data center restrictions, while defense stocks could face spending limits and healthcare may benefit. Stocks have historically tended to rise after midterms, but some worry the S&P 500's strong 2026 gains could break that pattern.
- Prediction: At 1.6 Million Robots, Optimus Is “Greater Than the Revenue From Tesla.” Musk Sees 625x That
Venture capitalist Dave Blundin said on the Moonshots podcast that Optimus robot revenue could exceed Tesla's own revenue if the company builds 1.6 million robots a year, while Elon Musk has predicted well over a billion humanoid robots within 10 years. At $30,000 a robot, Tesla would need to sell about 4 million Optimus units to match the $122 billion in revenue analysts expect for 2027, while the company expects first deliveries to outside customers around the end of 2027. Tesla trades at 187x forward earnings, compared with a five-year average of 108x, and its latest quarterly GAAP operating margin was 2.6%. The author says he would want to see Optimus shipping to outside customers before paying for the stock's current valuation.
- Google Recently Warned That Quantum Computers Could Crack Bitcoin. Now It's Selling Protection.
On Oct. 28, Google Cloud previewed a new crypto custody system aimed at banks offering crypto products to clients. Its Multi-Party Compute (MPC) service splits each private key into fragments stored on separate systems; hacked or illegally obtained private keys accounted for 43.8% of crypto stolen in 2024, per Chainalysis, and commercial launch is planned for early 2027. Google Cloud revenue rose 103% year over year to $30.7 billion in the third quarter, but the author sees little reason MPC will meaningfully benefit Alphabet, given unknown pricing and many competitors. The article also notes MPC does not stop attacks that work backward from public keys, which expose more than 6 million bitcoins, almost 29% of the supply, held in wallets with exposed public keys.
- Binance's net inflows turn positive at $2.3B as withdrawals expand
Binance recorded $2.3 billion in net inflows over the past 24 hours, reversing Monday's outflows of more than $7 billion, as it expanded withdrawals after the $6.3 billion hack on Thursday. Binance led centralized exchanges tracked by DefiLlama; Bitfinex saw about $280 million and Bitget about $127 million. Binance said hourly deposits exceeded withdrawals by 03:00 UTC. The exchange had suspended withdrawals on Friday, began restoring them at 06:00 UTC on Sunday, and said it had replaced about 95% of the affected assets, with the remaining 5% being less liquid tokens. It pledged to cover the losses using company resources and protection funds without passing them on to customers. The FBI attributed the attack to North Korea, which denied responsibility on Tuesday.
- Azimut Undertakes New Mineral Resource Estimate on the Patwon Gold Deposit, James Bay Region, Québec
Azimut Exploration is preparing a new NI 43-101 mineral resource estimate for the Patwon gold deposit on its Elmer Property in Québec's James Bay region, using results from its 2026 diamond drilling program and the current higher gold price. The 2026 program drilled 10 holes totaling 5,407.05 metres, shorter than the planned 10,000 metres due to severe winter conditions, and intersected additional gold mineralization near the current resource shell. Norda Stelo is preparing the update, expected by the end of 2026; the 2023 estimate at US$1,800 per ounce reported 311,200 ounces indicated and 513,900 ounces inferred. The Elmer structural corridor spans 43 kilometres, including a gold anomaly 3.6 kilometres to the east grading up to 583 g/t Au. Azimut is also advancing its Wabamisk project, where significant drilling is planned for later this year and in 2027.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.